Core Viewpoint - The company, Pulaike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Fluralaner Chewable Tablets," which is aimed at treating external parasites in dogs [1] Group 1: Product Approval - The new veterinary drug has been officially registered and is set to be effective as of January 7, 2026, following the issuance of the New Veterinary Drug Registration Certificate [1] - The approval was granted based on the regulations outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] Group 2: Indications and Usage - The drug is indicated for the treatment of external parasites in dogs, specifically targeting ticks (Rhipicephalus sanguineus) and fleas (Ctenocephalides felis, Ctenocephalides canis) [1] - It can also be used as part of a treatment plan for flea allergy dermatitis [1]

普莱柯公告称，经农业农村部审查，批准公司及全资子公司洛阳惠中兽药有限公司等联合申报的"氟雷 拉纳咀嚼片"为新兽药，并公示核发《新兽药注册证书》。该兽药为二类，主要成分氟雷拉纳，用于治 疗犬体表蜱虫、跳蚤感染。其驱杀作用可持续12周，采用软咀嚼片制备工艺，适口性好。产品上市前还 应取得兽药产品批准文号，这对公司提升竞争力、推动宠物板块业绩增长有积极作用。 ...

格隆汇1月8日丨普莱柯(603566.SH)公布，根据《兽药管理条例》和《兽药注册办法》规定，经农业农 村部审查，批准公司及全资子公司洛阳惠中兽药有限公司等单位联合申报的"氟雷拉纳咀嚼片"为新兽 药，并于2026年1月7日公示了核发《新兽药注册证书》（中华人民共和国农业农村部公告第986号）事 项。 适应症：用于治疗犬体表的蜱虫（血红扇头蜱）、跳蚤（猫栉首蚤、犬栉首蚤）感染，可作为控制跳蚤 过敏性皮炎方案的一部分来应用。 ...

从资金流向上来看，当日动物保健板块主力资金净流入1429.81万元，游资资金净流出3379.23万元，散户 资金净流入1949.42万元。动物保健板块个股资金流向见下表： 证券之星消息，1月6日动物保健板块较上一交易日上涨0.83%，*ST绿康领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 37.17 | 5.00% | 7510.0 | 2772.39万 | | 300871 | 回盛生物 | 21.92 | 3.15% | 9.40万 | 2.03亿 | | 920970 | 大禹生物 | 7.95 | 2.71% | 1.84万 | 1449.96万 | | 920729 | 永顺生物 | 8.90 | 2.06% | 1.12万 | 992.55万 | | 920275 | 驱动力 | 9.05 | 1.57% | 1.01 ...

Investment Rating - The report does not explicitly provide an investment rating for the pet healthcare industry in China. Core Insights - The pet healthcare industry in China is experiencing rapid growth, with a significant increase in the number of pet hospitals and a shift towards chain operations. The report highlights the launch of New Ruipeng's "Thousand-Store Initiative" as a pivotal moment in this transformation [1][5][24]. Summary by Sections Industry Overview - The report focuses on the pet hospital industry in China, analyzing its layout, treatment volume, and business models to understand the current development status and market size [3][4]. Market Growth and Structure - As of 2024, there are 22,320 registered animal treatment institutions in mainland China, marking a 10% increase from 2023, with a compound annual growth rate (CAGR) of 8.7% from 2020 to 2024. Single hospitals still dominate the market, accounting for 78.9% of the total, while chain institutions represent 21.1% [5][8]. - The distribution of pet hospitals is uneven, with Guangdong leading at 2,408 hospitals, followed by Jiangsu with 2,218. First-tier and new first-tier cities account for 36.3% of the total number of pet hospitals [8] . Treatment Types and Consumer Satisfaction - In 2023-2024, the treatment for pet dogs is primarily focused on medical care, increasing from 47.6% to 49.0%. For cats, the immunization rate is between 39.8% and 40.5%, with nearly 36% for medical treatment, indicating a diverse medical demand [14]. - Consumer satisfaction regarding treatment services fluctuated, with satisfaction rates dropping from 70.8% in 2023 to 66.2% in 2024. The main dissatisfaction stems from high prices and lack of transparency, with 50.7% and 53.5% of consumers citing these issues in 2023 and 2024, respectively [14][19]. Financial Performance and Market Dynamics - The market shows a complex landscape, with no significant overall growth in monthly revenue, but changes in revenue structure. The proportion of institutions with monthly revenue below 100,000 yuan has slightly increased, while the average customer price has seen a slight rise in 2024 [21]. - Profit margins have generally declined, with a 5% decrease in 2024 compared to the previous year, indicating increased competition and the need for cost control and service quality improvement [21][19]. Competitive Landscape - The report identifies a competitive landscape dominated by three major players: New Ruipeng, Ruipai, and Ruichen, which have established a "three-strong" competitive structure. These companies focus on service quality and operational efficiency rather than merely expanding the number of stores [24][30]. - The report emphasizes the need for continuous innovation and enhancement of competitive capabilities among pet healthcare chains to adapt to market changes and meet evolving consumer demands [30]. Financing Environment - The pet industry has seen fluctuations in private equity and venture capital financing, with a peak of 82 events in 2021, followed by a sharp decline to 29 events in 2024. This indicates a cautious investment climate as the industry transitions into a new phase of quality improvement [28][30]. Future Trends - The report suggests that the future of the pet healthcare industry will focus on specialization and digitalization, with leading chain hospitals optimizing resources and exploring lower-tier markets to drive growth [31].

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Insights - The report highlights a significant rebound in pork prices before the New Year, with the average price of lean pigs reaching 12.39 CNY/kg, a 7.6% increase from the previous week, although it remains 19.7% lower year-on-year [5][13][23] - The implementation of a safeguard policy for beef import quotas is expected to alleviate domestic supply pressures, with a total import quota of 2.688 million tons for 2026, which is 93.5% of the total imports in 2024 [14] - The report recommends focusing on leading companies with cost advantages in the livestock sector, particularly Wens Foodstuff and Muyuan Foods, while also highlighting potential turnaround candidates like Zhengbang Technology [5][13] Livestock Farming - The report notes that the pork market is under pressure due to significant losses in the industry, but the reduction in production capacity is expected to accelerate, leading to a more stable price environment in the first half of 2026 [5][13] - For poultry, the average price of white feather chickens is reported at 3.78 CNY/lb, down 3.1% week-on-week, while yellow feather chicken prices have shown slight increases, benefiting companies like Lihua and Wens [5][13][32] Dairy Industry - The current price of fresh milk in major production areas is 3.03 CNY/kg, stable week-on-week but down 3.2% year-on-year, indicating a balance in supply and demand as inventory levels decrease [14] - The safeguard measures on beef imports are anticipated to support domestic beef prices, which are expected to rise, enhancing the performance of companies like Yurun and Modern Farming [14] Feed and Animal Health - The report indicates a rebound in aquaculture prices due to holiday demand, with significant increases in white shrimp prices leading up to the New Year [15] - The feed industry is facing intense competition, but leading companies are expected to gain market share due to their cost advantages, especially in international markets [15] Agricultural Sector Performance - The agricultural sector outperformed the market by 0.7 percentage points, with livestock farming and feed sectors showing the highest gains of 1.4% and 0.5%, respectively [21] - The report tracks various agricultural product prices, noting fluctuations in corn and soybean meal prices, with corn prices rising by 0.6% to 2352 CNY/ton [23][46]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Group 1 - The core view of the report emphasizes a structural transformation in the capital market, focusing on rebuilding confidence and addressing external demand pessimism [3][4] - The investment logic suggests a shift from cyclical growth to cyclical value, with a resilient cycle expected in 2026, highlighting the value attributes of leading companies [9] - Key assumptions include a gradual decrease in the breeding sow inventory and proactive capacity control by pig companies, which may lead to reduced supply pressure and potential price recovery for pigs in 2026 [8] Group 2 - The report identifies specific companies to focus on, such as leading low-cost and high-certainty firms like Muyuan Foods and Wens Foodstuffs, as well as high-growth smaller pig companies [7] - The report outlines potential risks, including the possibility of breeding sow inventory not decreasing as expected, which could lead to an oversupply of pigs and downward pressure on prices [8] - The report also discusses the beef market, indicating that if the import impact continues, it could lead to downward pressure on beef prices, affecting the profitability of beef companies [16][24] Group 3 - In the poultry sector, the report highlights that the yellow chicken market may see price increases if breeding stocks continue to decline, while the white chicken market is expected to recover as macroeconomic activities improve [25][26] - The report emphasizes the importance of consumer demand in the poultry market, noting that weak demand could lead to price declines and pressure on company performance [27][32] - The report suggests that the animal health sector will benefit from the recovery of livestock profitability, with a focus on companies that have strong R&D capabilities and product pipelines [33][36] Group 4 - The grain sector is expected to see upward price trends due to adverse weather conditions affecting crop yields, with a focus on companies involved in seed production and transgenic varieties [40][41] - The report warns of potential risks in the seed industry, including weak demand for new varieties, which could lead to price declines and increased pressure on seed companies [44][45] - The report highlights the importance of monitoring government policies regarding the commercialization of new seed varieties, as delays could impact market expectations [46][48] Group 5 - The report provides a risk assessment for recommended stocks, such as Muyuan Foods and Wens Foodstuffs, indicating potential risks related to pig output and price declines [50][56] - The report emphasizes the need for continuous monitoring of key indicators, such as breeding sow inventory and market prices, to assess the performance of the companies in the livestock sector [56]

证券之星消息，12月30日动物保健板块较上一交易日下跌0.91%，生物股份领跌。当日上证指数报收于 3965.12，下跌0.0%。深证成指报收于13604.07，上涨0.49%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1.05亿元，游资资金净流入4812.36万元，散户资 金净流入5735.09万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002141 | 赔丰控股 | 3.83 | 4.08% | 37.86万 | 1.44亿 | | 300119 | 瑞普生物 | 19.19 | 0.00% | 3.36万 | 6454.17万 | | 603566 | 普莱柯 | 12.50 | -0.16% | 2.70万 | 3375.65万 | | 920729 | 永顺生物 | 8.68 | -0.23% | 4725.43 | 409.76万 | | 300871 | 回盛生物 | 20.64 | -0.29% | ...